.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Luke Nordquist, MD

Articles

Dr. Luke Nordquist on Who Should Receive Radium-223

October 21st 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

September 17th 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.